Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Net Cash Flow: 2009-2025

Historic Net Cash Flow for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to -$399,799.

  • China Pharma Holdings' Net Cash Flow fell 1194.31% to -$399,799 in Q3 2025 from the same period last year, while for Sep 2025 it was -$417,862, marking a year-over-year increase of 37.78%. This contributed to the annual value of -$764,365 for FY2024, which is 19.80% down from last year.
  • Per China Pharma Holdings' latest filing, its Net Cash Flow stood at -$399,799 for Q3 2025, which was down 257.31% from $254,149 recorded in Q2 2025.
  • China Pharma Holdings' Net Cash Flow's 5-year high stood at $4.4 million during Q4 2021, with a 5-year trough of -$1.4 million in Q2 2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$65,874 (2024), whereas its average is -$157,362.
  • In the last 5 years, China Pharma Holdings' Net Cash Flow spiked by 9,298.63% in 2023 and then slumped by 1,835.09% in 2024.
  • Over the past 5 years, China Pharma Holdings' Net Cash Flow (Quarterly) stood at $4.4 million in 2021, then slumped by 101.36% to -$60,201 in 2022, then surged by 105.86% to $3,528 in 2023, then crashed by 1,835.09% to -$61,214 in 2024, then tumbled by 1,194.31% to -$399,799 in 2025.
  • Its Net Cash Flow stands at -$399,799 for Q3 2025, versus $254,149 for Q2 2025 and -$210,998 for Q1 2025.